CN1694694A - 神经性厌食症(an)和贪食症的治疗 - Google Patents

神经性厌食症(an)和贪食症的治疗 Download PDF

Info

Publication number
CN1694694A
CN1694694A CNA038251698A CN03825169A CN1694694A CN 1694694 A CN1694694 A CN 1694694A CN A038251698 A CNA038251698 A CN A038251698A CN 03825169 A CN03825169 A CN 03825169A CN 1694694 A CN1694694 A CN 1694694A
Authority
CN
China
Prior art keywords
epa
purposes
treatment
acid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038251698A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·F·霍罗宾
阿格尼丝·艾顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laxdale Ltd
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1694694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of CN1694694A publication Critical patent/CN1694694A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA038251698A 2002-09-16 2003-09-16 神经性厌食症(an)和贪食症的治疗 Pending CN1694694A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0221480.7 2002-09-16
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia

Publications (1)

Publication Number Publication Date
CN1694694A true CN1694694A (zh) 2005-11-09

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038251698A Pending CN1694694A (zh) 2002-09-16 2003-09-16 神经性厌食症(an)和贪食症的治疗

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276262A (zh) * 2018-07-30 2019-01-29 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20070082949A1 (en) * 2003-11-14 2007-04-12 Hiroaki Ootani Agent for preventing and treating language disorders
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JPWO2008081989A1 (ja) 2006-12-28 2010-04-30 サントリーホールディングス株式会社 神経再生剤
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
ES2561482T3 (es) 2007-02-15 2016-02-26 Centre De Recherche Sur Les Biotechnologies Marine Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
KR102012111B1 (ko) * 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
WO2012109539A1 (en) * 2011-02-11 2012-08-16 E. I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
AU2019217673A1 (en) 2018-02-07 2020-09-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
WO2019204218A1 (en) * 2018-04-16 2019-10-24 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
WO2021195627A1 (en) * 2020-03-27 2021-09-30 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276262A (zh) * 2018-07-30 2019-01-29 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统

Also Published As

Publication number Publication date
WO2004024136A1 (en) 2004-03-25
IS7744A (is) 2005-03-15
MXPA05002943A (es) 2005-06-03
KR20050042823A (ko) 2005-05-10
TW200410682A (en) 2004-07-01
BR0317857A (pt) 2005-12-06
RU2330653C2 (ru) 2008-08-10
HRP20050245A2 (en) 2005-10-31
CA2499142A1 (en) 2004-03-25
US20060135608A1 (en) 2006-06-22
RS20050226A (sr) 2007-09-21
NO20051847L (no) 2005-04-15
AU2003269138A1 (en) 2004-04-30
NZ538793A (en) 2007-05-31
ZA200502161B (en) 2005-09-15
EP1556028A1 (en) 2005-07-27
JP2006503031A (ja) 2006-01-26
PL375726A1 (en) 2005-12-12
GB0221480D0 (en) 2002-10-23
RU2005107416A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
CN1694694A (zh) 神经性厌食症(an)和贪食症的治疗
Haas et al. Therapeutic effects of a ketogenic diet in Rett syndrome
Schapiro Managing the symptoms of multiple sclerosis
Hillard et al. Bulimia and diabetes: a potentially life-threatening combination
Al-Mosawi The treatment of a child with birth asphyxia induced brain atrophy, adrenal hemorrhage, and bi-lateral hyperoxaluric nephrocalcinosis: A challenging case and a unique experience
JP2011241209A (ja) ガングリオシド又はその誘導体を有効成分とするｂｄｎｆ産生促進剤並びにそれを含有する医薬品、飲食品及び飼料
CN110420225A (zh) 一种用于防治骨关节炎的组合物及其制备方法和应用
Janssen Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
JP2016525134A (ja) チグリンアルデヒドを使用する組成物及び方法
JP2016525132A (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
CN102085357B (zh) 原料含有水蛭素、纤溶素的药物的用途
Steadman Herpes simplex mimicking functional psychosis
Bukowiecka-Matusiak et al. Age-and obesity-related metabolic changes and their impact on the incidence of digestion, metabolism, and immune health
Gross Aspects of bulimia
Fauteck The Magic of Melatonin: How this Amazing Hormone Will Help You Sleep, Reduce Pain, Relieve Anxiety, Slow Aging, and Much More
JP2016525133A (ja) クミンアルデヒドを使用する組成物及び方法
Saini et al. Critical Analysis of Etiological Factors of Ajirna (Indigestion)
US20200261485A1 (en) Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions
Cobb Stiff man syndrome: is the lesion at spinal cord or brain stem level
RU2282453C2 (ru) Способ терапии больных сахарным диабетом ii типа
Kumar Social and preventive health administration
Djordjević Dictionary of medicine: French-English with English-French glossary
Anderson Development & Changes in Digestion & Sleep
Stunkard et al. Surgical treatment of obesity
Liggan et al. Taking Care of Our Folks: A Manual for Family Members Caring for the Black Elderly

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication